Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Kaposi 3Lymphoproliferative Disorders 3Epstein-Barr Virus Infections 3Multi-centric Castleman's Disease 2Lymphoma 2Acquired Immunodeficiency Syndrome 2Stomach Neoplasms 1Pyloric Stenosis, Hypertrophic 1Neoplasms 1Nasopharyngeal Carcinoma 1Macular dystrophy, corneal type 1 1Lymphoma, Extranodal NK-T-Cell 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Hodgkin Disease 1Head and Neck Neoplasms 1HIV Infections 1Glioblastoma 1EBV Lymphomas 1Cytomegalovirus Infections 1Castleman Disease 1Brain Neoplasms 1

Interventions

Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Immune Reconstitution Inflammatory Syndrome × Valganciclovir × Clear all
NCT03296553 2022-01-27

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

National Institute of Cancerología

Phase 2 Completed
40 enrolled 6 charts
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Immune Reconstitution Inflammatory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡